BibTex format
@article{Vieira:2026:10.1111/all.70305,
author = {Vieira, RJ and Sousa-Pinto, B and Bousquet, J and Schünemann, HJ and Zuberbier, T and Bognanni, A and Togias, A and Samolinski, B and Valiulis, A and Williams, S and Bedbrook, A and Czarlewski, W and Torres, MJ and Shamji, MH and Morais-Almeida, M and Canonica, GW and Vecillas, LDL and Dykewicz, MS and Jacomelli, C and Klimek, L and Leemann, L and Lourenço, O and Papadopoulos, NG and Pereira, AM and Savouré, M and Toppila-Salmi, SK and Ventura, MT and Yepes-Nuñez, JJ and Cruz, AA and Ciprandi, G and Gemicioglu, B and Giovannini, M and Gradauskiene, B and Jartti, T and Jeseák, M and Kuna, P and Kvedariene, V and Larenas-Linnemann, DE and Latiff, AHA and Mohammad, Y and Ohta, K and Mahesh, PA and Pali-Schöll, I and Pfaar, O and Regateiro, FS and Roche, N and Taborda-Barata, L and Ulrik, CS and Viegi, G and Zhang, L and Haahtela, T and Cherrez-Ojeda, I and Ivancevich, JC and Khaltaev, N and Yorgancioglu, A and Abdullah, B and Al-Ahmad, M and Al-Nesf, MA and Amaral, R and Asllani, J and Be},
doi = {10.1111/all.70305},
journal = {Allergy},
title = {Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part II-Guidelines on Oral and Ocular Treatments.},
url = {http://dx.doi.org/10.1111/all.70305},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)-EAACI guidelines, this manuscript presents the ARIA-EAACI 2024-2025 recommendations for oral and ocular treatments. METHODS: The ARIA-EAACI 2024-2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgements and recommendations, including systematic reviews, mHealth and pharmacovigilance data as well as a survey on costs. RESULTS: Eight guideline questions concerning oral treatments for AR and three questions concerning ocular treatments were addressed. These questions led to the recommendations. Overall, these questions concern the choice between different classes of medication. They also discuss the role of oral antihistamines (OAH), leukotriene receptor antagonists (LTRA), ocular antihistamines (OcAH) and ocular mast cell stabilisers. Four questions had not been previously evaluated in ARIA guidelines, while, for the other four, there was a change in the strength or directionality of the recommendations. Overall, these guidelines recommend using intranasal corticosteroids over OAH and using OAH over LTRA. Moreover, they suggest using OAH over OcAH and suggest being against adding LTRA to OAH. Finally, considerations for choosing between different individual OAHs are presented. CONCLUSION: This ARIA-EAACI 2024-2025 article supports patients, their caregivers and healthcare professionals in choosing oral and ocular treatments for AR. Decisions on treatment should consider the clinical variability of the disease, patients' values and the affordability of medications.
AU - Vieira,RJ
AU - Sousa-Pinto,B
AU - Bousquet,J
AU - Schünemann,HJ
AU - Zuberbier,T
AU - Bognanni,A
AU - Togias,A
AU - Samolinski,B
AU - Valiulis,A
AU - Williams,S
AU - Bedbrook,A
AU - Czarlewski,W
AU - Torres,MJ
AU - Shamji,MH
AU - Morais-Almeida,M
AU - Canonica,GW
AU - Vecillas,LDL
AU - Dykewicz,MS
AU - Jacomelli,C
AU - Klimek,L
AU - Leemann,L
AU - Lourenço,O
AU - Papadopoulos,NG
AU - Pereira,AM
AU - Savouré,M
AU - Toppila-Salmi,SK
AU - Ventura,MT
AU - Yepes-Nuñez,JJ
AU - Cruz,AA
AU - Ciprandi,G
AU - Gemicioglu,B
AU - Giovannini,M
AU - Gradauskiene,B
AU - Jartti,T
AU - Jeseák,M
AU - Kuna,P
AU - Kvedariene,V
AU - Larenas-Linnemann,DE
AU - Latiff,AHA
AU - Mohammad,Y
AU - Ohta,K
AU - Mahesh,PA
AU - Pali-Schöll,I
AU - Pfaar,O
AU - Regateiro,FS
AU - Roche,N
AU - Taborda-Barata,L
AU - Ulrik,CS
AU - Viegi,G
AU - Zhang,L
AU - Haahtela,T
AU - Cherrez-Ojeda,I
AU - Ivancevich,JC
AU - Khaltaev,N
AU - Yorgancioglu,A
AU - Abdullah,B
AU - Al-Ahmad,M
AU - Al-Nesf,MA
AU - Amaral,R
AU - Asllani,J
AU - Bergmann,K-C
AU - Bernstein,JA
AU - Blaiss,MS
AU - Toskala,E
AU - Carreiro-Martins,P
AU - Casale,T
AU - Cecchi,L
AU - Fiocchi,A
AU - Giuliano,AFM
AU - Christoff,G
AU - Cirule,I
AU - de,Sousa JC
AU - Costa,EM
AU - Devillier,P
AU - Hossny,E
AU - Iinuma,T
AU - Ispayeva,Z
AU - Julge,K
AU - Kaidashev,I
AU - Bennoor,KS
AU - Kraxner,H
AU - Kull,I
AU - Kulus,M
AU - Kupczyk,M
AU - Kurchenko,A
AU - La,Grutta S
AU - Miculinic,N
AU - Tuyet,LLT
AU - Lee,SM
AU - Montefort,S
AU - Moreira,A
AU - Mullol,J
AU - Nadif,R
AU - Nakonechna,A
AU - Neffen,HE
AU - Niedoszytko,M
AU - O'Hehir,RE
AU - Ogulur,I
AU - Okamoto,Y
AU - Olze,H
AU - Palomares,O
AU - Panzner,P
AU - Patella,V
AU - Pitsios,C
AU - Puggioni,F
AU - Quirce,S
AU - Ramonaité,A
AU - Repka-Ramirez,MS
AU - Roberts,G
AU - Robles-Velasco,K
AU - Rottem,M
AU - Salapatas,M
AU - Sastre,J
AU - Scichilone,N
AU - Sisul,J-C
AU - Solé,D
AU - Soto-Martinez,ME
AU - Sova,M
AU - Tantilipikorn,P
AU - Todo-Bom,A
AU - Tsaryk,V
AU - Tsiligianni,I
AU - Urrutia-Pereira,M
AU - Valovirta,E
AU - Vasankari,T
AU - Wallace,D
AU - Wang,DY
AU - Worm,M
AU - Yusuf,OM
AU - Gil-Mata,S
AU - Marques-Cruz,M
AU - Mahboub,B
AU - Romano,A
AU - Aberer,W
AU - Artesani,MC
AU - Azzolini,E
AU - Barreto,B
AU - Bartra,J
AU - Becker,S
AU - Beghe,B
AU - Boner,A
AU - Borowiack,E
AU - Bouchard,J
AU - Brussino,L
AU - Buhl,R
AU - Catamerò,F
AU - Charpin,D
AU - Chavannes,NH
AU - Chemiska,M
AU - Cheng,L
AU - Chkhartishvili,E
AU - Cho,SH
AU - Chong-Neto,HJ
AU - Chu,DK
AU - Cingi,C
AU - Compalati,E
AU - Costa,RA
AU - Cvetkovski,B
AU - Cardona,V
AU - D'Amato,G
AU - Davies,JM
AU - Di,Bona D
AU - Gonzalez,Diaz SN
AU - Dimou,MV
AU - Doulaptsi,M
AU - Ferre
DO - 10.1111/all.70305
PY - 2026///
TI - Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part II-Guidelines on Oral and Ocular Treatments.
T2 - Allergy
UR - http://dx.doi.org/10.1111/all.70305
UR - https://www.ncbi.nlm.nih.gov/pubmed/41877472
ER -